IDRA-21 vs NSI-189
A side-by-side research comparison of IDRA-21 and NSI-189 across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | IDRA-21 | NSI-189 |
|---|---|---|
| Full name | IDRA-21 (Benzothiadiazide AMPA PAM) | NSI-189 Phosphate (Neurogenic Compound) |
| Category | Cognitive & Nootropic | Cognitive & Nootropic |
| Status | Research compound | Investigational |
| Mechanism | Binds AMPA receptors allosterically, reducing desensitization rates to prolong excitatory currents and facilitate LTP for memory encoding. | Stimulates hippocampal neural stem cell proliferation and differentiation via Akt/CREB/BDNF signaling. Increases hippocampal volume visible on MRI. |
| Molecular weight | 262.7 Da | 366.4 Da |
| Half-life | 8-12 hours (effects persist 48-72h) | 18-22 hours |
| Bioavailability | High (oral) | High (oral) |
| Typical dose | 10-30 mg | 40-80 mg |
| Frequency | 2-3x per week | Once daily |
| Route | Oral | Oral |
IDRA-21 reported benefits
- AMPA receptor potentiation
- Enhanced memory consolidation
- Improved learning speed
- Long-lasting effects
- Oral bioavailability
NSI-189 reported benefits
- Hippocampal neurogenesis
- Measurable brain volume increase
- Cognitive enhancement
- Antidepressant effects
- Long-term neural benefit
Related comparisons
Research and educational reference only. Not medical advice.